Table 1. Baseline clinical characteristics of COVID‐19 patients and control subjects at admission.

Characteristic	Control group, median	COVID-19 group, median	p value	Mild COVID-19 patients group median	Moderate COVID-19 patients group median	Severe COVID-19 patients group median	Critical COVID-19 patients group median	p value
Age (yrs) (min-max)	58.5 (22-82)	61.3 (23-94)	0.205	57 (28-73)	60.5 (41-82)	61 (23-94)	70.5 (35-81)	0.201
Gender			0.531					0.271
Male, n (%)	51 (55.4%)	44 (52.3%)		8 (47.1%)	24 (53.3%)	12 (75%)	5 (41.7%)
Female, n (%)	41 (44.6%)	40 (47.6%)		9 (52.9%)	21 (46.7%)	4 (25%)	7 (58.3%)
Comorbidity	41 (45.1%)	51 (54.3%)	0.264	10 (58.8%)	22 (48.9%)	7 (43.8%)	10 (83.3%)	0.141
Hypertension	25 (28.4%)	33 (36.7%)		6 (35.3%)	14 (31.1%)	7 (43.8%)	6 (50%)	0.598
Diabetes	18 (20.4%)	22 (24.4%)		4 (23.5%)	8(17.8%)	5 (31.3%)	5 (41.7%)	0.331
COPD	9 (10.2%)	12 (13.3%)		1 (5.9%)	2 (6.7%)	3 (12.5%)	6 (50%)	0.001*
CAD	9 (10.7%)	11 (12.2%)		0	4 (8.9%)	4 (25%)	3 (25%)	0.039*
Cerebrovascular disease	1 (1.1%)	1 (1.1%)		-	1 (2.2%)	0	0	0.780
Chronic kidney disease	5 (5.6%)	4 (4.4%)		1 (5.9%)	3 (6.7%)	0	0	0.592
Viral hepatitis	-	1 (1.1%)		0	0	0	1 (8.3%)	0.056
Asthma	6 (6.8%)	4 (4.4%)		0	2 (4.4%)	1 (6.3%)	1 (8.3%)	0.858
Symptom-sign
Fever	-	47 (51.6%)		7 (14.9%)	24 (51.1%)	9 (19.1%)	7 (14.9%)	0.665
Dyspnea	-	46 (50.5%)		6 (13%)	20 (43.5%)	11 (23.9%)	9 (19.6%)	0.045*
Cough	-	42 (46.2%)		6 (14.3%)	23 (54. %8)	6 (14.3%)	7 (16.7%)	0.418
Weakness	-	27 (29.7%)		8 (29.6%)	14(51.9%)	2 (7.4%)	3(11.1%)	0.230
Sore throat	-	9 (9.9%)		4 (44.4%)	2 (22.2%)	2 (22.2%)	1 (11.1%)	0.226
Anosmia	-	5 (5.5%)		1 (20%)	2 (40%)	-	2 (40%)	0.271
Diarrhea	-	11 (12.1%)		2 (18.2%)	4 (36.4%)	2 (18.2%)	3 (27.3%)	0.506
Chest pain	-	5 (5.5%)			3 (60%)	1 (20%)	1 (20%)	0.372
Headache	-	4 (4.4%)		1 (25%)	1 (25%)	2 (50%)	-	0.306
Joint pain	-	17 (18.7%)		8 (47.1%)	7 (41.2%)	-	2 (11.8%)	0.008*

*p<0.05 was considered statistically significant; COPD = chronic obstructive pulmonary disease; CAD = coronary artery disease